How it works
Sermorelin binds GHRH receptors on pituitary somatotrophs, triggering pulsatile endogenous GH release. The natural feedback loop is preserved, reducing the risks of supraphysiologic GH exposure seen with direct HGH.
The evidence
FDA-approved (since withdrawn from commercial production but available via compounding pharmacies) for pediatric GH deficiency. Adult use is off-label, supported by limited but consistent data showing modest IGF-1 increases and improvements in body composition and sleep.
Typical dosing
200–500 mcg subcutaneous nightly before bed, 5 nights per week. Courses typically 3–6 months with re-evaluation.
Side effects
Common
- Injection-site reactions
- Flushing
Less common
- Headache
- Nausea
Rare
- Hypersensitivity reactions
Drug interactions
- Glucocorticoids — may reduce GH response
- Insulin — monitor glucose with GH-mediated insulin resistance